Pharmaceutical Supply and Manufacturing

The contract involves the manufacture and supply of 2,000 packages of LOPERAMIDE HYDROCHLORIDE CAPSULES under strict regulatory standards including FDA regulations, current Good Manufacturing Practices (cGMP), and Defense Logistics Agency (DLA) requirements. This subcontract is part of a pharmaceutical supply initiative managed by the Department of Defense through the Defense Logistics Agency, ensuring the product meets federal quality and compliance benchmarks for military and government use. The North American Industry Classification System code 325412 confirms the focus on pharmaceutical and medicine manufacturing, and the contract was posted on August 5, 2026, indicating the timeline for fulfillment and delivery. All production and packaging activities must adhere to the specified regulatory frameworks to guarantee safety, efficacy, and traceability of the medication. The place of performance and point of contact details are not provided, but the award is linked to the DIBBS system under contract SPE2DX25D9900 and delivery order SPE2DP26F8761, confirming its official status within DLA’s procurement framework. Compliance with these requirements is mandatory, and failure to meet standards could result in rejection of the supply or contractual penalties. The quantity and product specification suggest this is a targeted replenishment or logistics effort for use in military medical operations.